FedSearch
Ajay Major, MD, MBA · @majorajay
144 followers · 142 posts · Server med-mastodon.com

Exciting news! Mosunetuzumab just FDA approved for R/R follicular lymphoma after 2 lines of therapy. A great option for our patients.

finance.yahoo.com/news/fda-app

#lymsm #tcellrx

Last updated 2 years ago
Original post

Yan Leyfman, MD · @yleyfman
108 followers · 97 posts · Server med-mastodon.com

#cancerawareness #cancerawarenessmonth #cancer #oncology #Immunotherapy #CARTCells #genetherapy #cartcellrx #medicine #CellTherapy #tcellrx #cart #genetx #Chernobyl #patient #chernobylsurvivor #patientadvocate #patientnavigator #geneticengineering #advocate #advocacy #patientcare #together #patientsupport #cancercoalition #cancerresearch #survivor #caretaker #PersonalizedMedicine #growth

Last updated 2 years ago
Original post

Ajay Major, MD, MBA · @majorajay
142 followers · 137 posts · Server med-mastodon.com
Open media

A huge thank you to the @CUHematology@twitter.com advanced practice providers for the invitation to give an educational talk today about approaches to managing relapsed DLBCL after CAR T-cell therapy.

#lymsm #tcellrx

Last updated 2 years ago
Original post

Ajay Major, MD, MBA · @majorajay
131 followers · 120 posts · Server med-mastodon.com
Open media

Found a CEA of pola-R-CHP at that did not include CAR-T (unlike Dr. @SwethaKMD@twitter.com analysis) which found that ICER varied widely based on long-term survival. Important implications in areas without access to CAR.

#ash22 #lymsm #tcellrx

Last updated 2 years ago
Original post

Ajay Major, MD, MBA · @majorajay
131 followers · 120 posts · Server med-mastodon.com
Open media

RT @majorajay@twitter.com

Critically important study by Dr. @SwethaKMD@twitter.com calculating QALYs for pola-R-CHP from POLARIX, which are dependent on cost of CAR-T. Dovetails well with our forthcoming paper on clinician impressions of POLARIX with @dgermain21@twitter.com @Eddie_Cliff@twitter.com @ErmannMD@twitter.com @UDurani@twitter.com.

#tcellrx

Last updated 2 years ago
Original post

Ajay Major, MD, MBA · @majorajay
128 followers · 88 posts · Server med-mastodon.com
Open media

Regarding our data on checkpoint inhibitors: now 3 datasets presented that survival is abysmal with PD1/PDL1 blockade in relapsed disease after CAR-T. Great work by Drs. @gloria_iacoboni@twitter.com & Erbella that bispecifics & pola have much better salvage outcomes.

#ash22 #lymsm #tcellrx

Last updated 2 years ago
Original post

Ajay Major, MD, MBA · @majorajay
128 followers · 87 posts · Server med-mastodon.com

I made it on @lymphomahub@twitter.com?! Thank you so much for attending and a huge thanks to my @UCCancerCenter@twitter.com fellowship mentors and all our co-investigators.

#ash22 #lymsm #tcellrx

Last updated 2 years ago
Original post

Kamran Mirza MD PhD :verified: · @kamran
166 followers · 501 posts · Server med-mastodon.com
Open media

RT @majorajay@twitter.com

1. 3622 Hayes: PRO dashboard co-designed by docs & transplant pts. Worse physical/social fxn & fatigue 1 month post SCT, returned to baseline by 3-6 mos. Dashboard helped pts better discuss symptoms with clinical team. This is the goal of PROs!

ashpublications.org/blood/arti

🐦🔗: twitter.com/majorajay/status/1

#tcellrx

Last updated 2 years ago
Original post

Kamran Mirza MD PhD :verified: · @kamran
166 followers · 460 posts · Server med-mastodon.com
Twitter - Ajay Major, MD, MBA on Twitter

RT @majorajay@twitter.com

The most important trial at : NEUTRODIET, a randomized multicenter trial of 'neutropenic diet' vs normal diet after auto/alloSCT. No differences in infections, aGHVD or hospital days between arms. Less weight loss & better patient satisfaction in normal diet arm! t.co/kXosgjUypr

🐦🔗: twitter.com/majorajay/status/1

#ash22 #tcellrx

Last updated 2 years ago
Original post

Ajay Major, MD, MBA · @majorajay
125 followers · 72 posts · Server med-mastodon.com
Open media

Going on simulataneously in the aggressive lymphoma session: hyperferritinemia, receipt of tisa-cel CAR-T product, and elevated LDH were risk factors for inferior PFS and OS in patients with ICANS / neurotoxicity during CAR-T therapy.

#ash22 #lymsm #tcellrx

Last updated 2 years ago
Original post

Ajay Major, MD, MBA · @majorajay
125 followers · 71 posts · Server med-mastodon.com
Open media

The most important trial at : NEUTRODIET, a randomized multicenter trial of 'neutropenic diet' vs normal diet after auto/alloSCT. No differences in infections, aGHVD or hospital days between arms. Less weight loss & better patient satisfaction in normal diet arm!

#ash22 #tcellrx

Last updated 2 years ago
Original post

Kamran Mirza MD PhD :verified: · @kamran
159 followers · 389 posts · Server med-mastodon.com
Open media

RT @VJHemOnc@twitter.com

A pleasure catching up with @niravshahmd@twitter.com (@MedicalCollege@twitter.com) at , who spoke on the safety and tolerability of pirtobrutinib monotherapy in patients with B-cell malignancies previously intolerant to a covalent BTKi and LV20.19 CAR-T!
@ASH_Hematology@twitter.com

🐦🔗: twitter.com/VJHemOnc/status/16

#ash22 #HemOnc #lymsm #tcellrx

Last updated 2 years ago
Original post

Yan Leyfman, MD · @yleyfman
89 followers · 53 posts · Server med-mastodon.com

#safety #CellTherapy #celltherapies #Immunotherapy #genetherapy #cellulartherapeutics #IO #cancer #oncology #dlbcl #lymphoma #cartecells #cartcellrx #NKcells #nkcars #bispecifics #tcellengagers #BloodCancers #MultipleMyeloma #solidtumors #breastcancer #gicancer #CARTCell #CARTCells #msc #mesenchymalstemcells #mesenchymalstemcell #crispr #crisprcas9 #geneediting #checkpointinhibitors #BMT #bmtrx #bmtsm #tcellrx

Last updated 2 years ago
Original post

Ajay Major, MD, MBA · @majorajay
121 followers · 38 posts · Server med-mastodon.com

A huge thanks again to all of our collaborators who helped make this study possible. Looking forward to seeing you all at @ASH_hematology@twitter.com very soon!

#ash22 #bmtsm #lymsm #tcellrx

Last updated 2 years ago
Original post

Ajay Major, MD, MBA · @majorajay
121 followers · 38 posts · Server med-mastodon.com
Open media

RT @CULymphoma@twitter.com

Our newest @CULymphoma@twitter.com faculty member Dr. @majorajay@twitter.com is presenting an oral abstract at regarding a multicenter study of survival outcomes in patients treated with checkpoint inhibitors after CAR-T relapse. cc @CUHematology@twitter.com

ashpublications.org/blood/arti

#ash22 #lymsm #tcellrx

Last updated 2 years ago
Original post

Yan Leyfman, MD · @yleyfman
25 followers · 9 posts · Server med-mastodon.com

#Immunotherapy #CARTCells #genetherapy #cartcellrx #medicine #CellTherapy #tcellrx #cart #genetx #Chernobyl #patient #chernobylsurvivor #patientadvocate #patientnavigator #geneticengineering #crispr #cellulartherapeutics #LLMCongress2022 #healthcare #success #innovation #research #grateful #growth #mentorship #msc #msctherapy #stemcell #stemcells #stemcellrx

Last updated 2 years ago
Original post

Ajay Major, MD, MBA · @majorajay
58 followers · 11 posts · Server med-mastodon.com
Open media

Preparing for my first ASH oral presentation at ! We have much more work to do for patients with relapsed lymphomas after CAR-T.

A huge thanks to my mentor Dr. Kline and all of our participating centers.

ash.confex.com/ash/2022/webpro

#ash22 #lymsm #tcellrx

Last updated 2 years ago
Original post